Products Safinamide is commercially available in the form of film-coated tablets (Xadago). It was approved in many countries and in the EU in 2015 and in the US in 2017. Structure and properties Safinamide (C17H19FN2O2, Mr = 302.3 g/mol) is an α-aminoamide derivative. Effects Safinamide (ATC N04BD03) has indirect dopaminergic properties. It is a selective … Safinamide
Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors
Products Degarelix is commercially available as a powder and solvent for solution for injection (Firmagon). It was approved in many countries in February 2010. Structure and properties Degarelix is a decapeptide derived from gonadotropin-releasing hormone (GnRH), a hormone of the hypothalamus. It is present in drugs as degarelix acetate and differs from the natural substance … Degarelix
Products Bufexamac was on the market in many countries as a cream and as an ointment (Parfenac). Because the active ingredient frequently causes allergic contact dermatitis, distribution of the drugs was discontinued. Structure and properties Bufexamac or 2-(4-butoxyphenyl)–hydroxyacetamide (C12H17NO3, Mr = 223.3 g/mol) is a white to almost white crystalline powder that is practically insoluble … Bufexamac
